IS7262A - Myndlaus og kristölluð form lósartankalíums og aðferð til að framleiða þau - Google Patents

Myndlaus og kristölluð form lósartankalíums og aðferð til að framleiða þau

Info

Publication number
IS7262A
IS7262A IS7262A IS7262A IS7262A IS 7262 A IS7262 A IS 7262A IS 7262 A IS7262 A IS 7262A IS 7262 A IS7262 A IS 7262A IS 7262 A IS7262 A IS 7262A
Authority
IS
Iceland
Prior art keywords
amorphous
producing
crystalline forms
losartan potassium
losartan
Prior art date
Application number
IS7262A
Other languages
English (en)
Inventor
Zion Dolitzky Ben
Wizel Shlomit
Nisnevich Gennady
Rukhman Igor
Kaftanov Julia
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS7262A publication Critical patent/IS7262A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS7262A 2001-11-14 2004-05-13 Myndlaus og kristölluð form lósartankalíums og aðferð til að framleiða þau IS7262A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33303401P 2001-11-14 2001-11-14
US40127802P 2002-08-05 2002-08-05
PCT/US2002/036550 WO2003048135A1 (en) 2001-11-14 2002-11-13 Amorphous and crystalline forms of losartan potassium and process for their preparation

Publications (1)

Publication Number Publication Date
IS7262A true IS7262A (is) 2004-05-13

Family

ID=26988524

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7262A IS7262A (is) 2001-11-14 2004-05-13 Myndlaus og kristölluð form lósartankalíums og aðferð til að framleiða þau

Country Status (16)

Country Link
US (2) US7332612B2 (is)
EP (1) EP1458693A4 (is)
JP (2) JP2006504618A (is)
KR (1) KR20050044450A (is)
CN (1) CN1612866A (is)
AU (1) AU2002360386A1 (is)
CA (2) CA2465597A1 (is)
ES (1) ES2234451T1 (is)
HR (1) HRP20040510A2 (is)
HU (1) HUP0501067A2 (is)
IL (1) IL161970A0 (is)
IS (1) IS7262A (is)
MX (1) MXPA04004657A (is)
NO (1) NO20042434L (is)
PL (1) PL374442A1 (is)
WO (1) WO2003048135A1 (is)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DE60315417T2 (de) * 2002-10-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von losartan kaliumsalz mit verbesserten fliesseigenschaften
WO2004039352A2 (en) * 2002-10-31 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of losartan potassium
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2003209669A1 (en) * 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
ITMI20030328A1 (it) * 2003-02-25 2004-08-26 Dinamite Dipharma S P A In Forma A Bbreviata Diph Polimorfi di losartan potassio e procedimento per la loro preparazione.
WO2004076442A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphs of losartan
US7345071B2 (en) 2003-05-07 2008-03-18 Ipca Laboratories Limited Process for the synthesis of Losartan potassium
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ITMI20032472A1 (it) * 2003-12-16 2005-06-17 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di losartan potassio cristallino
EP1709034A2 (en) * 2004-01-06 2006-10-11 IPCA Laboratories Limited An improved process for the synthesis of losartan potassium
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
EP1729766A1 (en) * 2004-03-01 2006-12-13 LEK Pharmaceuticals D.D. Pharmaceutical formulation
EP1737449A1 (en) * 2004-03-01 2007-01-03 LEK Pharmaceuticals D.D. Pharmaceutical composition
US20050250827A1 (en) * 2004-05-05 2005-11-10 Etinger Marina Y Preparation of candesartan cilexetil in high purity
RU2373923C2 (ru) * 2004-06-08 2009-11-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции
CA2581926A1 (en) 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20090076281A1 (en) * 2005-05-05 2009-03-19 Medichem, S.A. Process for the preparation of losartan and its salts
CN101277950B (zh) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007049292A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US20070225297A1 (en) 2006-03-16 2007-09-27 Perni Robert B Deuterated hepatitis C protease inhibitors
MX2009009182A (es) * 2007-02-27 2009-09-04 Vertex Pharma Co-cristales y composiciones farmaceuticas que los comprenden.
EP2134717A2 (en) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
NZ583699A (en) * 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
LT3345625T (lt) 2008-08-13 2021-02-10 Vertex Pharmaceuticals Incorporated Farmacinė kompozicija ir jos vartojimas
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
NZ594738A (en) 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
NZ603044A (en) 2010-04-22 2015-08-28 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011242452A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CA2798412A1 (en) 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CA2809263A1 (en) 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
AU2012332225A1 (en) 2011-11-02 2014-05-15 Vertex Pharmaceuticals Incorporated Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
WO2018183367A1 (en) 2017-03-28 2018-10-04 Van Goor Fredrick F Methods of treating cystic fibrosis in patients with residual function mutations
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019010092A1 (en) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
US20210228489A1 (en) 2017-12-04 2021-07-29 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3752510B1 (en) 2018-02-15 2022-12-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
WO2019191620A1 (en) 2018-03-30 2019-10-03 Vertex Pharmaceuticals Incorporated Crystalline forms of modulators of cftr
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2019381750B2 (en) 2018-11-14 2025-08-07 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN113453760B (zh) 2018-12-17 2024-05-24 弗特克斯药品有限公司 Apol1抑制剂及其使用方法
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2020242935A1 (en) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
CA3162219A1 (en) 2019-12-20 2021-06-24 Pasit Phiasivongsa Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CA3183591A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
CN116157393A (zh) 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
JP2023550345A (ja) 2020-11-17 2023-12-01 バーテックス ファーマシューティカルズ インコーポレイテッド ４－（５－（４－フルオロフェニル）－６－（テトラヒドロ－２ｈ－ピラン－４－イル）－１，５－ジヒドロピロロ［２，３－ｆ］インダゾール－７－イル）安息香酸の固体形態
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
KR20240155228A (ko) 2022-02-03 2024-10-28 버텍스 파마슈티칼스 인코포레이티드 (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
US20250340568A1 (en) 2022-05-16 2025-11-06 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
EP4540250A1 (en) 2022-06-14 2025-04-23 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1- yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2024031081A1 (en) 2022-08-04 2024-02-08 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases
GEAP202516730A (en) 2022-09-09 2025-07-25 Vertex Pharma Modulators of alpha-i antitrypsin
WO2025076240A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
EP4648753B1 (en) 2024-02-07 2026-02-18 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases
WO2025193777A1 (en) 2024-03-13 2025-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of alpha-1 antitrypsin modulators
WO2026006653A1 (en) 2024-06-28 2026-01-02 Vertex Pharmaceuticals Incorporated Combination comprising exacaftor/tezacaftor/ivacaftor for use in treating cystic fibrosis where the patient has at least one cftr mutation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
US5130439A (en) 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
US5206374A (en) 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
US5310928A (en) 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
JP3266395B2 (ja) * 1993-11-24 2002-03-18 富士写真フイルム株式会社 有機薬品の晶析方法
CA2179067A1 (en) * 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
CA2186606A1 (en) 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
JPH1085502A (ja) * 1996-09-19 1998-04-07 Konica Corp 晶析方法

Also Published As

Publication number Publication date
US7332612B2 (en) 2008-02-19
HUP0501067A2 (en) 2006-02-28
AU2002360386A1 (en) 2003-06-17
KR20050044450A (ko) 2005-05-12
CN1612866A (zh) 2005-05-04
CA2465597A1 (en) 2003-06-12
US20080096945A1 (en) 2008-04-24
US20040006237A1 (en) 2004-01-08
EP1458693A4 (en) 2005-02-09
NO20042434L (no) 2004-06-11
PL374442A1 (en) 2005-10-17
IL161970A0 (en) 2005-11-20
JP2009173685A (ja) 2009-08-06
WO2003048135A1 (en) 2003-06-12
HRP20040510A2 (en) 2005-08-31
EP1458693A1 (en) 2004-09-22
MXPA04004657A (es) 2004-08-13
CA2672549A1 (en) 2003-06-12
JP2006504618A (ja) 2006-02-09
ES2234451T1 (es) 2005-07-01

Similar Documents

Publication Publication Date Title
IS7262A (is) Myndlaus og kristölluð form lósartankalíums og aðferð til að framleiða þau
GB2394120B (en) Method of producing electroluminescent element
PL374600A1 (en) Method of producing honeycomb structures
GB0111207D0 (en) A method to produce germanium layers
SG115572A1 (en) A novel method of fabricating variable length vertical transistors
IL163735A (en) Method of producing a shaped tampon
DK1401445T3 (da) Krystallinsk anticholinergikum, fremgangsmåde til fremstilling af dette og anvendelse af dette til fremstilling af et lægemiddel
DK1295509T3 (da) Fremgangsmåde til fremstilling af en otoplastik og en tilsvarende otoplastik
IS7600A (is) Aðferð til að stuðla að reykbindindi
PL364164A1 (pl) Struktura plastra pszczelego zawierająca Si oraz sposób jej wytwarzania
NO20035738L (no) Kontrollert frigivelsessammensetning og metode for a produsere det samme
EP1541721A4 (en) PROCESS FOR PRODUCING A SILICON MONOCRYSTAL
SG104355A1 (en) Method of forming a novel top-metal fuse structure
GB2421805B (en) Method of forming diffractive optical elements
IL157372A0 (en) Method for producing reduced-weight plasterboards
AU2003213718A8 (en) Method of producing antigens
NO20022409D0 (no) En kalsium-silikat basert slagg og metode for å produsere et kalsium-silikat basert slagg
DK1419992T3 (da) Anlæg og fremgangsmåde til at fremstille syntesegas
GB2403740B (en) A structural truss and method for forming a structural truss
TWI347932B (en) Producing method of purified 2-cyanoacrylates
NO20040400L (no) Lettkonstruksjonselement og fremgangsmate for fremstilling av dette.
GB0230129D0 (en) Method of fabricating a device
EP1667802A4 (en) METHOD FOR PRODUCING A WAVE STRUCTURE
AU2003278422A8 (en) Amorphous form of losartan potassium
AU2003286666A1 (en) Method to solids-pack non-vertical wellbores